Recent studies have led to important insights regarding the role of viruses in asthma pathogenesis and exacerbations, as well as mediating factors involved in these processes.
Researchers found limited clinical variability between PIV serotypes and substantial overlap in presenting signs and symptoms for PIV and other etiologies.
A phase 3 study of tocilizumab (Actemra®) for the treatment of hospitalized patients with severe COVID-19 pneumonia did not meet its primary and key secondary end points.
The FDA has granted Orphan Drug designation to INO-3107, a DNA plasmid immunotherapy, for the treatment of recurrent respiratory papillomatosis, a rare disease caused by human papillomavirus types 6 and 11 infections.
New clinical practice guidelines for the treatment of nontuberculous mycobacterial pulmonary disease were published by leading respiratory medicine and infectious disease societies.
Treatment with daptomycin for bacteremia caused by methicillin-resistant Staphylococcus aureus complicated by septic pulmonary emboli was found to have a success rate comparable to daptomycin-ceftaroline fosamil.
A team of investigators conducted a retrospective cohort study to determine the risk of subdeltoid bursitis associated with the administration of the influenza vaccine.
A study revealed that primary care clinicians do not closely follow clinical practice guidelines with regard to antibiotic prescribing for acute sinusitis and frequently overprescribe antibiotics.
A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.
Risk factors for bronchiectasis in patients with AERD include older age as well as the presence of allergic bronchopulmonary aspergillosis, aspiration, mycobacterial infection, and pneumonia.
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
